As an example, EGFR mutations and ALK fusions are estimated to be present, on average, in 15% and 5% of NSCLC patients in the U.S., respectively, yet the clinical evidence illustrates that the rates of CGP testing is much lower than what is recommended based on clinical guidelines for patients with NSCLC50–52. Here, ALK is linked to non-small cell lung carcinoma.